We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In today's competitive drug development market, biopharmaceutical businesses are always under pressure to provide high-quality medicines swiftly and affordably.
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours.
China is a “big cancer country” with the population attacked by cancers ranking first in the world, which is a problem the Chinese patients and medical workers have to face.